Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase NA 1Phase 2 1

Status

Completed 8Terminated 1

Sponsor Class

OTHER 5INDUSTRY 3NIH 1

Study Type

Interventional 9

Sponsor

Cancer Type

Other hematologic neoplasm 152Lymphoid 73Myeloid 62Gastrointestinal 25Breast 22Thoracic 17CNS 17Genitourinary 16Sarcoma 12Plasma cell 12Dermatologic 10Tumor-Agnostic 9Other solid neoplasm 8Head & Neck 7Gynecologic 6Classical hematology 1

Conditions

Neoplasms 5Neoplasm Metastasis 4

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

9 trials
RecentStart dateEnrollment
Interventional × Dasatinib × Tumor-Agnostic × Clear all
NCT01445509 2026-06-05

Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
50 enrolled
Tumor-Agnostic

Neoplasms

NCT01744652 2023-06-07

Dasatinib and Crizotinib in Advanced Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
62 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01015222 2022-11-23

Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Completed
122 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01636908 2021-04-15

ICK

Amsterdam UMC, location VUmc

Phase NA Completed
43 enrolled
Tumor-Agnostic

Neoplasms

NCT00717704 2020-08-05

Solid Tumors Using Ixabepilone and Dasatinib

Medstar Health Research Institute

Phase 1 Completed
19 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT02142036 2019-03-13

MetAction

Oslo University Hospital

Phase 2 Completed
50 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT00099606 2011-04-19

Phase I (PH I) Mad Refractory Solid Tumor Study

Bristol-Myers Squibb

Phase 1 Completed
60 enrolled
Tumor-Agnostic

Neoplasms

NCT00162214 2011-04-14

Study of Dasatinib in Patients With Advanced Solid Tumors

Bristol-Myers Squibb

Phase 1 Terminated
60 enrolled
Tumor-Agnostic

Neoplasms

NCT00339144 2010-12-15

Study of Dasatinib (BMS-354825) in Patients With Solid Tumors

Bristol-Myers Squibb

Phase 1 Completed
16 enrolled 29 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡